IAVI | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

BRIEF

published on 09/25/2024 at 14:55, 1 month 25 days ago

Africa CDC and IAVI Sign MoU to Boost Vaccine and Antibody Research in Africa

Vaccine Development MoU Antibody Research Africa CDC IAVI Partnership
BRIEF

published on 09/25/2024 at 14:55, 1 month 25 days ago

Le CDC Afrique et l'IAVI signent un protocole d'accord pour stimuler la recherche sur les vaccins et les anticorps en Afrique

Protocole D'accord Développement De Vaccins Recherche Sur Les Anticorps Centre De Contrôle Et De Prévention Des Maladies D'Afrique Partenariat IAVI
PRESS RELEASE

published on 09/25/2024 at 14:50, 1 month 25 days ago

Africa CDC and IAVI Sign Memorandum of Understanding to Enhance Vaccine and Antibody Research Capacity in Africa
Africa CDC and IAVI sign MoU to enhance disease-fighting capacity and pandemic readiness in Africa, focusing on vaccine and antibody development, supply resilience, and health security

Vaccine Development IAVI MoU Africa CDC Health Security
BRIEF

published on 04/04/2024 at 15:05, 7 months 16 days ago

First Phase 2 Clinical Trial of Lassa Fever Vaccine Begins in Nigeria

Phase 2 Clinical Trial Global Health Lassa Fever Vaccine IAVI CEPI
BRIEF

published on 04/04/2024 at 15:05, 7 months 16 days ago

Début du premier essai clinique de phase 2 du vaccin contre la fièvre de Lassa au Nigeria

Santé Mondiale IAVI CEPI Vaccin Contre La Fièvre De Lassa Essai Clinique De Phase 2
PRESS RELEASE

published on 04/04/2024 at 15:00, 7 months 16 days ago

Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
CEPI-funded study in Nigeria evaluates safety, tolerability, and immunogenicity of IAVI's Lassa fever vaccine candidate. First Phase 2 trial for any Lassa vaccine

Phase 2 Trial IAVI CEPI Lassa Fever Vaccine Candidate
PRESS RELEASE

published on 12/18/2023 at 15:00, 11 months 2 days ago

IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB Vaccine Candidate in Africa
PRESS RELEASE

published on 07/07/2023 at 15:00, 1 year 4 months ago

Germany Issues Award to IAVI to Support Development of the MTBVAC Tuberculosis Vaccine Candidate
PRESS RELEASE

published on 06/27/2023 at 15:00, 1 year 4 months ago

IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate
PRESS RELEASE

published on 05/17/2023 at 15:00, 1 year 6 months ago

Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC

Accesswire

Published on 11/21/2024 at 09:00, 39 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 4 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 14 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 39 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 39 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 38 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 39 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 39 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 24 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 29 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 32 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE